Clinical Guidelines for Somatostatin Receptor Imaging and Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumor (2022)

Title: Clinical Guidelines for Somatostatin Receptor Imaging and Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumor (2022)
Edition: Original
Classification: Standard guideline
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users:
Evidence classification method: This consensus mainly includes two types of evidence: First, high-level evidence-based medical evidence (Category 1), which is unanimously agreed by the expert group and strongly recommended (A); Second, the level of evidence is slightly lower (Category 2), but the expert group basically agrees, and it is moderately recommended (B). Other levels of evidence will not be currently included.
Development unit: Chinese Society of Nuclear Medicine, Chinese Neuroendocrine Tumor Society
Registration time: 2022-04-15
Registration number: IPGRP-2022CN229
Purpose of the guideline: